



## Inify Laboratories establishes its UK laboratory at Milton Park

Inify is establishing its UK laboratory within *Nebula*, a pioneering research and development workspace at Milton Park - one of the UK's leading science and technology clusters, located just outside Oxford, in South Oxfordshire.

Nebula, named [Best Commercial Building](#) of the Year at the OxProp Awards 2025, provides a state-of-the-art setting for innovation. Within this environment, Inify is replicating its proven Swedish laboratory system in the UK, ensuring the same standards of efficiency, image quality, reporting speed, and diagnostic accuracy.

**Kate Bucknall, Managing Director of Inify UK, said:** “Our new base at Milton Park is a real milestone in our mission to improving cancer care and reducing delays in patient pathways. Our recent success shows that digitised, AI-supported workflows can halve the time from biopsy to diagnosis, which has been transformative for both patients and clinicians in Sweden.

Read the full press release published by Milton Park [here](#).

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardised and AI- supported workflow to optimise quality and response times, initially within prostate – and now expanding into gastroenterology. The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off from [ContextVision](#), with 40 years of experience within digital imaging for medical applications. The company's share is listed on [Euronext Growth Oslo under the ticker INIFY](#).